A share price of ImmunityBio Inc [IBRX] is currently trading at $3.04, up 27.20%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IBRX shares have gain 18.75% over the last week, with a monthly amount glided 5.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on January 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $6. Previously, Piper Sandler downgraded its rating to Neutral on May 12, 2023, and dropped its price target to $4. On August 03, 2022, Jefferies initiated with a Buy rating and assigned a price target of $8 on the stock.
ImmunityBio Inc experienced fluctuations in its stock price throughout the past year between $2.28 and $10.53. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $3.04 at the most recent close of the market. An investor can expect a potential return of 97.37% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
Trailing Twelve Months sales for ImmunityBio Inc [NASDAQ:IBRX] were 7.33M which represents 7346.34% growth. Gross Profit Margin for this corporation currently stands at -0.24% with Operating Profit Margin at -49.0%, Pretax Profit Margin comes in at -80.19%, and Net Profit Margin reading is -80.17%. To continue investigating profitability, this company’s Return on Assets is posted at -1.61, Equity is 0.86 and Total Capital is -1.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.61 points at the first support level, and at 2.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.26, and for the 2nd resistance point, it is at 3.48.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ImmunityBio Inc [NASDAQ:IBRX] is 2.68. Further, the Quick Ratio stands at 2.64, while the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 302.82.
